Gestational Diabetes

What it is

Gestational diabetes is high blood sugar first recognized during pregnancy, usually screened for at 24–28 weeks. It happens when the body cannot make enough insulin to meet the higher insulin resistance of pregnancy. The most important practical fact is that untreated gestational diabetes raises the risk of complications for both mother and baby, but monitoring, food planning, activity, and medicines when needed can greatly reduce those risks.

Gestational diabetes mellitus, often called GDM or pregnancy diabetes, does not always cause symptoms. Many people feel well and are diagnosed only through routine blood glucose testing during prenatal care. GDM is different from diabetes that was already present before pregnancy, although some people first found to have high glucose in pregnancy may actually have previously unrecognized type 2 diabetes.

Why it matters:

Main concern	Examples
Maternal risks	High blood pressure, preeclampsia, cesarean birth, later type 2 diabetes
Fetal and newborn risks	Large birth weight, birth injury, newborn low blood sugar, breathing problems
Long-term risks	Higher future risk of obesity and glucose problems in the child, and diabetes in the mother

In India, GDM is a major public health issue because South Asian populations have a high background risk of insulin resistance and type 2 diabetes. Screening practices may vary by clinician, hospital, and guideline used.

How it works

Pregnancy naturally makes the body more insulin resistant, especially in the second and third trimesters. Placental hormones such as human placental lactogen, progesterone, cortisol, and growth hormone help support fetal growth, but they also reduce how well insulin works. To keep blood sugar normal, the pancreas must increase insulin secretion.

GDM develops when this increase in insulin production is not enough. In many patients, there is a combination of underlying insulin resistance and limited beta-cell reserve. Risk is higher with older maternal age, overweight or obesity, family history of diabetes, prior GDM, prior large baby, polycystic ovary syndrome, and some ethnic backgrounds including South Asian ancestry.

High maternal glucose crosses the placenta, but maternal insulin does not. The fetus responds by making more insulin. Fetal hyperinsulinemia can drive excess growth, especially more body fat, which is why babies may be large for gestational age. After birth, the glucose supply from the mother stops suddenly, but the baby's insulin may remain high for a time, causing neonatal hypoglycemia.

Diagnosis / how it's measured

Most guidelines recommend screening during pregnancy, commonly at 24 to 28 weeks, though earlier testing may be done if risk is high. There are 2 main diagnostic approaches in current use:

Approach	How it is done	Notes
One-step	75 g oral glucose tolerance test after fasting	Used by some international groups; more sensitive but identifies more cases
Two-step	50 g glucose challenge test, then 100 g oral glucose tolerance test if abnormal	Common in some practices, especially in the US

Different professional bodies use different glucose thresholds, so the same person may meet criteria under one system and not another. That is one reason reported prevalence varies widely across studies and countries.

Diagnosis is based on blood glucose values, not symptoms. HbA1c alone is not the standard test for diagnosing GDM because it is less sensitive for pregnancy-related glucose changes. Once GDM is diagnosed, patients are usually asked to monitor fasting and post-meal glucose at home to guide treatment.

Clinicians also assess fetal growth and maternal blood pressure, and they may order additional monitoring later in pregnancy depending on glucose control and other risks.

Evidence and uses

The main goal of treatment is to keep glucose in target range and lower the chance of complications. Strong evidence supports treatment of GDM, especially when it includes nutrition therapy, physical activity, glucose monitoring, and medication if targets are not met.

Typical management includes:

1. Medical nutrition therapy: balanced meals, controlled carbohydrate distribution, and avoidance of large glucose spikes.
2. Physical activity: regular movement, such as walking after meals if approved by the obstetric team.
3. Self-monitoring of blood glucose: fasting and post-meal checks are commonly used.
4. Medication when needed: insulin is often preferred when lifestyle measures are not enough; metformin is used in some settings, but practice varies.

Treatment reduces rates of excessive fetal growth and some birth complications. Good glucose control also lowers the risk of preeclampsia and operative delivery, though it does not remove risk completely.

After delivery, blood sugar often returns to normal, but follow-up is essential. People with prior GDM have a substantially increased risk of developing type 2 diabetes later in life. Postpartum glucose testing is therefore recommended, followed by long-term screening every few years depending on the guideline and the patient's risk profile.

Breastfeeding is encouraged when possible, as it has maternal and infant health benefits and may help postpartum metabolic health.

When to see a clinician

Routine prenatal care is the main way GDM is found, so keeping scheduled pregnancy visits is important even if you feel well. Contact your obstetric clinician promptly if you have marked thirst, frequent urination beyond usual pregnancy changes, blurred vision, reduced fetal movements, severe headache, swelling, or high home glucose readings.

You should also seek review if you cannot keep food or fluids down, have repeated low glucose episodes during treatment, or are unsure how to use insulin or a glucose meter. Urgent assessment is needed for symptoms of preeclampsia, labor concerns, or decreased baby movement.

After pregnancy, do not skip postpartum diabetes testing. This follow-up matters because GDM can be the first sign of an underlying tendency toward type 2 diabetes.

Limitations and open questions

There is broad agreement that GDM is important to detect and treat, but there is still debate about the best screening strategy and diagnostic thresholds. One-step testing identifies more cases, while two-step testing may reduce overdiagnosis and resource use. Researchers continue to study which approach gives the best balance of benefit, cost, and practicality.

Another open question is how best to individualize treatment targets and medication choices. Insulin has the longest track record in pregnancy, but metformin is widely studied and used in some settings; long-term child outcomes remain an area of active research.

Evidence is also evolving on prevention, including whether diet pattern changes before or early in pregnancy can lower GDM risk in high-risk groups. In India and other countries with high diabetes burden, improving access to standardized screening and postpartum follow-up remains a major challenge.

Most people with GDM go on to have healthy pregnancies, but the condition needs structured care rather than self-treatment. If you are pregnant or planning pregnancy and have risk factors for diabetes, discuss screening and follow-up with your obstetric clinician.